Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative intravenous lidocaine during radical colorectal cancer resection
ChiCTR2400081309Phase 4Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lidocaine in colorectal cancer (CRC) (2 arms), sponsored by Shanxi Cancer Hospital. Primary endpoint: Change in peripheral venous NK cell proportion. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
lidocaine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400081309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081309.